Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium

Enterococcus faecium, a significant nosocomial pathogen, has developed resistance to multiple antibiotics, stimulating a search for new effective antimicrobials. The new quinolone trovafloxacin (CP-99,219) has good in-vitro activity against Gram-positive cocci, including E. faecium. We evaluated the...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 39; no. 4; pp. 552 - 553
Main Authors Herrera-Insúa, I, Jacques-Palaz, K, Murray, B E, Rakita, R M
Format Journal Article
LanguageEnglish
Published England 01.04.1997
Subjects
Anti-Bacterial Agents - pharmacology
Anti-Infective Agents - pharmacokinetics
Anti-Infective Agents - pharmacology
Dose-Response Relationship, Drug
Drug Resistance, Microbial
Enterococcus faecium
Enterococcus faecium - drug effects
Fluoroquinolones
Humans
Microbial Sensitivity Tests
Naphthyridines - pharmacokinetics
Naphthyridines - pharmacology
Neutrophils - drug effects
Neutrophils - microbiology
Vancomycin - pharmacology
Online AccessGet full text

Cover

More Information
Summary:Enterococcus faecium, a significant nosocomial pathogen, has developed resistance to multiple antibiotics, stimulating a search for new effective antimicrobials. The new quinolone trovafloxacin (CP-99,219) has good in-vitro activity against Gram-positive cocci, including E. faecium. We evaluated the intracellular activity of trovafloxacin inside human neutrophils (PMNs) against three vancomycin-susceptible (UWHC 2145, GE-1 and 758) and three vancomycin-resistant (SH-4, VREH-1 and E-1) strains of E. faecium.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/39.4.552